Skip to main content
Glama
orphan-disease-opportunity-mcp

orphan-disease-opportunity-mcp

orphan-disease-opportunity-mcp

License: MIT Data License: CC BY 4.0 Python 3.10+ Live Atlas

Open Venture & Translational Opportunity Atlas — Model Context Protocol (MCP) Server
Flagship Deep-Dive #1: JAK2 V617F Myelofibrosis (jak2-myelofibrosis) • Web Dossier: https://rare-disease-atlas.github.io

mcp-name: io.github.rare-disease-atlas/orphan-disease-opportunity-mcp

An open, zero-third-party-dependency Python MCP server and OpenAPI 3.1 toolkit designed for technical founders (Computational / AI-Bio, Public Health Systems, Venture / Novel Financing) and autonomous AI research agents evaluating high-tractability orphan disease startups, drug-repurposing wedges, non-dilutive SBIR/venture-philanthropy grants, and ethical clinical validation pathways.


Instant 1-Command Installation (Zero PyPI Wait Required)

Run directly from GitHub via uvx with zero external runtime dependencies (pure Python >= 3.10 standard library):

uvx --from git+https://github.com/rare-disease-atlas/orphan-disease-opportunity-mcp orphan-disease-opportunity-mcp

(Once published to PyPI, uvx orphan-disease-opportunity-mcp also runs identically.)

Add to Claude Code (1 Command)

claude mcp add orphan-disease-opportunities -- uvx --from git+https://github.com/rare-disease-atlas/orphan-disease-opportunity-mcp orphan-disease-opportunity-mcp

Add to Claude Desktop / Cursor / Windsurf / Cline / Antigravity

Add to claude_desktop_config.json, .cursor/mcp.json, or your MCP client settings:

{
  "mcpServers": {
    "orphan-disease-opportunities": {
      "command": "uvx",
      "args": [
        "--from",
        "git+https://github.com/rare-disease-atlas/orphan-disease-opportunity-mcp",
        "orphan-disease-opportunity-mcp"
      ]
    }
  }
}

Related MCP server: Cofound Plugin

Why This Exists

Over 7,000 rare diseases carry FDA Orphan Drug Act structural advantages (7-year US market exclusivity, 100% waiver of the $4,682,003 FY2026 PDUFA filing fee, 25% qualified clinical trial tax credit, and N=120–350 pivotal trials), yet technical builders outside traditional wet-lab pharma rarely see where single-mutation structural tractability intersects urgent standard-of-care failure.

Flagship Case Study #1 (jak2-myelofibrosis) models this end-to-end:

  • Causal Precision: A single somatic mutation (JAK2 V617F in the JH2 pseudokinase autoinhibitory domain) drives ~50–60% of Primary Myelofibrosis (ORPHA:824, ~15,000–25,000 US patients).

  • First-Gen SoC Failure Cliff: All 4 FDA-approved JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) are Type I ATP-competitive binders of the conserved JH1 catalytic domain, inhibiting wild-type JAK2 alongside V617F—causing dose-limiting anemia/thrombocytopenia, ~50% discontinuation within 3 years, minimal clonal eradication, and 11–23 month median survival post-ruxolitinib failure.

  • Zero-Wet-Lab & Low-Capital Wedges: Structure-guided JH2 V617F vs WT (PDB: 4FVR/6E2Q/8BAK/8EX2 vs 4FVP) allosteric/PROTAC design + outsourced CRO screening; AI marrow fibrosis digital pathology (MF-0..3 composite endpoints solving the Phase 3 SVR35/TSS50 crisis); single-cell megakaryocyte-stroma drug repurposing (GSE144568, GSE156644); no-washout RWE clinical trial matching; allo-HSCT timing CDS; and evergreen venture-philanthropy SPVs.


Exposed MCP Capabilities

Tools (tools/list & tools/call)

Tool

Parameters

Capability

match_founder_opportunities

background (computational-ai-bio, public-health, venture-novel-financing, all), capital_tier (bootstrapped-grant, seed, series-a-platform, all), wet_lab_required (true/false), disease_id

Filters startup & translational blueprints with unit economics, regulatory pathways, open datasets, and 90-day milestones. Syncs live from https://rare-disease-atlas.github.io/opportunities.json with automatic fallback to bundled opportunities.json.

get_disease_case_study

disease_id (default "jak2-myelofibrosis")

Returns causal JH2 vs JH1 biology, Type I JAKi failure modes, FDA Orphan Drug economics, $1.7B–$2.9B M&A comps, and open PDB/GEO/ChEMBL/ClinicalTrials.gov accessions.

find_non_dilutive_grants

track (all, sbir-sttr, foundation, venture-philanthropy, regulatory-orphan, federal-translational)

Maps NCI/NHLBI SBIR, MPN Research Foundation (MPN Challenge), Blood Cancer United (TAP), Harrington Discovery Institute, FDA OOPD, and ARPA-H awards.

get_validation_communities

disease_id (default "jak2-myelofibrosis")

Maps institutional registries (MPN PROGRESSion Registry NCT07362225, HealthTree, Blood Cancer United CTSC, MPN Voice) paired with strict non-extractive ethical patient engagement rules.

Resource (resources/read)

  • briefing://rare-disease-playbook/jak2-myelofibrosis — Complete Markdown venture & translational playbook.

Prompt (prompts/get)

  • evaluate-rare-disease-venture — Multi-step 90-day killer-experiment, non-dilutive grant-stacking, and ethical validation workflow (founder_background, capital_budget, wet_lab_access).


Alternative Deployment Modes

Docker (Hardened Non-Root Container)

docker build -t orphan-disease-opportunity-mcp .

# Stdio MCP transport
docker run -i --rm orphan-disease-opportunity-mcp

# Remote Streamable HTTP MCP server (exposes POST /mcp, GET /.well-known/mcp.json, GET /health)
docker run --rm -p 8080:8080 orphan-disease-opportunity-mcp --transport http --host 0.0.0.0 --port 8080

Local Source Execution

git clone https://github.com/rare-disease-atlas/orphan-disease-opportunity-mcp.git
cd orphan-disease-opportunity-mcp
python3 -m orphan_disease_mcp

Custom GPT Actions & OpenAPI 3.1 Agents

Import openapi.yaml directly into OpenAI Custom GPT Actions, LangChain OpenAPIToolkit, or any OpenAPI 3.1 client to query https://rare-disease-atlas.github.io/opportunities.json over HTTPS with zero backend infrastructure.


Environment Variables (Optional)

Variable

Default

Description

ATLAS_DATA_URL

https://rare-disease-atlas.github.io/opportunities.json

Override URL for live JSON dataset sync.

ATLAS_OFFLINE

unset (0)

Set to 1 (true) to force deterministic offline execution from bundled opportunities.json.


Verification & Quality Assurance

Run the full zero-dependency end-to-end test suite (covers stdio JSON-RPC 2.0 lifecycle, all 4 tools, live HTTP mock sync + offline fallback, Streamable HTTP transport, and server.json / glama.json / smithery.yaml / openapi.yaml schema checks):

python3 test_mcp.py

License

Available Tools

5 tools
find_non_dilutive_grantsBInspect

Find non-dilutive SBIR/STTR, rare-disease foundation (MPNRF, Harrington), venture philanthropy (LLS TAP), FDA Orphan Products, and ARPA-H funding pathways.

Inputs: track.

get_disease_case_studyBInspect

Retrieve biological tractability, standard-of-care failure modes (e.g. Type I JH1 JAK inhibitor cytopenias vs JH2 V617F mutant selectivity), FDA Orphan Drug Act unit economics, and open structural/transcriptomic datasets for an orphan indication.

Inputs: disease_id.

get_validation_communitiesCInspect

Return established rare-disease patient & hematology clinical networks plus strict non-extractive ethical guidelines for founder problem discovery.

Inputs: disease_id.

match_founder_opportunitiesAInspect

Match high-tractability orphan disease startup & translational research blueprints by founder background, capital tier, and wet-lab requirement. Fetches live from rare-disease-atlas.github.io with bundled local fallback (Flagship Deep-Dive #1: JAK2 V617F Myelofibrosis).

Inputs: background, capital_tier, wet_lab_required.

submit_atlas_feedbackAInspect

Opt-in feedback & gap-reporting channel for AI agents and builders. Report missing founder wedges, requested orphan indications, new datasets, or ClinicalTrials.gov citation errata. Strictly exclude all personal identifiers (PII), patient health records, and confidential user IP.

Inputs: summary (required), disease_id, signal_type, agent_client, +1 more.

Tool Schema Changelog

Recent tool additions, removals, and schema changes observed during successful MCP inspections.

Loading tool schema changelog…

    TDQS

    A3.6/5.0

    Scored across 5 tools

    Disambiguation5/5

    Each tool targets a clearly distinct step in orphan-disease opportunity discovery: matching founders, retrieving disease case studies, finding grants, identifying validation communities, and submitting feedback. There is no meaningful overlap between the tools, and the descriptions make their boundaries explicit.

    Naming Consistency5/5

    All tool names use consistent snake_case with a clear verb_object pattern such as match_founder_opportunities, get_disease_case_study, and find_non_dilutive_grants. The naming is predictable and readable throughout.

    Tool Count5/5

    Five tools is well-scoped for this specialized workflow and each tool maps to a distinct need in the founder opportunity discovery process. None of the tools feels redundant or extraneous.

    Completeness4/5

    The surface covers the core lifecycle: opportunity matching, disease diligence, funding search, community validation, and feedback. Minor gaps remain, such as no explicit broad disease/opportunity search or deeper founder-blueprint retrieval separate from the matching tool, but agents can work around these through the existing tools.

    Maintenance

    ActivityNo data
    ResponsivenessOutdated data

    Related MCP Connectors

    Related MCP Servers